1. Generics Bulletin

Some Uncertainty Ahead For Towa Following Strong Financial Year

NHI Impact And Sunsho Acquisition Both Present Potential Risks

 
• By Chloe Kent

Towa performed well during the financial year ended 31 March, delivering a ¥15.9bn profit, but questions remain about the impact of Japan’s NHI drug price revision and its acquisition of Sunsho Pharmaceuticals going forward.

Businessman stood at crossroads
It remains to be seen whether Towa's Sunsho acquisition will prove itself a success • Source: Shutterstock

Japanese generics firm Towa delivered a respectable performance over its financial year ended 31 March 2022, yielding a net profit of ¥15.9bn ($118m) in the face of increased operational expenses and Japan’s April 2021 National Health Insurance drug price revision – but with reimbursement prices set to go down another 6.69% this year and Towa expected to be one of the most affected firms, the company should anticipate similar inconveniences in 2022.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business